Press Releases

View Archive: 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003

11.19.10
FibroGen Announces Phase 2a Results for Investigational Oral Anemia Therapy FG-4592 Will Be Presented at American Society of Nephrology (ASN) Renal Week

10.14.10
FibroGen Initiates Phase 2 Clinical Study to Evaluate Efficacy of FG-3019, Human Monoclonal Antibody Against CTGF, in Reversing Liver Fibrosis

9.20.10
FibroGen Announces Chinese State FDA Approval of FibroGen Oral Anemia Therapy, FG-4592

8.25.10
FibroGen Announces Results of 2-Year Study Demonstrating that Biosynthetic Corneas Formulated with Recombinant Human Type III Collagen Restore Vision and Promote Nerve Regeneration

5.25.10
Two Join Board of Directors of FibroGen, Inc.

5.17.10
FibroGen Reports Preclinical Data Showing that FG-3019 Reversed the Process of Fibrosis in the Lung